Serina Therapeutics IncNYSE American:SER
- LAST PRICE8.3000
- TODAY'S CHANGE (%)-0.5999 (-6.7405%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close8.5000 / 8.8999
- Day Range
- 52 Week Range
- Volume2,266
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SER |
|---|---|---|
| 02:33 ET | 100 | 8.3 |
| 03:59 ET | 0 | 8.3 |
Apr 17, 2024
DJ Serina Therapeutics Names Simba Gill as Executive Chairman, from 4:30PM ET on Wednesday Apr 17, 2024 by Dow Jones
4:30PM ET on Wednesday Apr 17, 2024 by Dow JonesSerina Therapeutics Appoints Dr. Simba Gill as Executive Chairman, from 4:05PM ET on Wednesday Apr 17, 2024 by Dow Jones
4:05PM ET on Wednesday Apr 17, 2024 by Dow JonesSerina Therapeutics Appoints Dr. Simba Gill as Executive Chairman, from 4:05PM ET on Wednesday Apr 17, 2024 by Dow Jones
4:05PM ET on Wednesday Apr 17, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Serina Therapeutics Inc | 20.8M | -0.6x | --- |
AIM ImmunoTech Inc | 20.6M | -0.7x | --- |
Evaxion Biotech A/S | 20.6M | 0.0x | --- |
Eom Pharmaceutical Holdings Inc | 20.8M | -4.2x | --- |
Alaunos Therapeutics Inc | 20.8M | -0.6x | --- |
Biomx Inc | 21.2M | -0.7x | --- |
Company Information
Serina Therapeutics, Inc., formerly AgeX Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of wholly owned drug product candidates to treat neurological diseases and pain. Its POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. Its POZ Platform partners are at the forefront in advancing LNP delivery technology to develop RNA therapeutics. The Company is focused on the advancement of its lead drug candidate, SER-252 (POZ-apomorphine), for the treatment of advanced Parkinson’s Disease through pre-clinical studies. The Company intends to advance SER 252 into Phase I clinical trials.
Contact Information
- Headquarters
- 1101 MARINA VILLAGE PARKWAY, SUITE 201ALAMEDA, CA, United States 94501
- Phone
- 510-671-8370
- Fax
- ---
Executives
- Executive Chairman of the Board
- Simba Gill
- Interim Chief Executive Officer, Director
- Steven Ledger
- Interim Chief Financial Officer, Chief Accounting Officer
- Andrea Park
- Chief Operating Officer, Company Secretary
- Tacey Viegas
- Chief Scientific Officer
- Randall Moreadith
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $20.8M |
|---|---|
Revenue (TTM) | $142.0K |
Shares Outstanding | 2.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.14 |
EPS | $-13.72 |
Book Value | $5.07 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 146.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -6,962.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
